http://graphenefrontiers.comConfidential and Proprietary

Medical biosensors play a major role in improving patients' quality of life.Global Medical Biosensors market forecasted to grow at CAGR 10.16% 2013-2018

Biosensors: $21B

1st Gen POC Diagnostics: Not Good Enough

• Limited Sensitivity• Slow • Inaccurate

Problem

Confidential and Proprietary

Next Gen POC Diagnostics: Quantum Leap

Graphene Field Effect Transistor (GFET) chips and Reader Device

Portable Reader

Confidential and Proprietary

Devices: GFET

GFET = Graphene Field Effect Transistor

Nobel Prize in Physics 2010

Confidential and Proprietary

ELISA GFET

Limit of Detection (LOD) 1-20pg/ml 100x-1000x better than ELISA

Ability to Multiplex No (1 antibody per run) Yes

Speed May take hours for incubation and processing Sample to results in minutes

Cost Expensive Optical Readers All electronic, lower cost

Ease of Use Trained Lab Tech Needed After sample obtained,the rest is automated

Specificity of detectionRelies on secondary detection antibody

Higher false positivesSpecific and direct

detection – all electronic

GF SIX BIOSENSOR PLATFORM

Graphene Frontiers Biosensors and IoT

GF Biosensors will transform healthcare and enable:

• Healthcare technology growth

• Healthcare connectivity

• Epidemiology studies at national level

• Big Data analytics

GF Biosensors will enable: (continued)

• Connection to CDC and generate alerts when infectious diseases arise in certain areas

• Easy and affordable diagnostics in rural areas

• Connection between small clinics and large medical centers to treat difficult diseases

Graphene Frontiers Biosensors and IoT

http://graphenefrontiers.comConfidential and Proprietary

Mike Patterson, CEOmike@graphenefrontiers.com

Victoria Tsai, SVP Business Development and Tech R&Dvictoria@graphenefrontiers.com